Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine

被引:30
作者
Saitoh, H
Saikachi, Y
Kobayashi, M
Yamaguchi, M
Oda, M
Yuhki, Y
Achiwa, K
Tadano, K
Takahashi, Y
Aungst, BJ
机构
[1] Hlth Sci Univ Hokkaido, Fac Pharmaceut Sci, Dept Pharmaceut, Ishikari, Hokkaido 0610293, Japan
[2] Sapporo City Gen Hosp, Dept Pharm, Sapporo, Hokkaido 0600011, Japan
[3] Quest Pharmaceut Serv, Newark, DE 19702 USA
关键词
tacrolimus; intestinal absorption; P-glycoprotein; metabolism; blood concentrations; rat small intestine;
D O I
10.1016/j.ejps.2005.12.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The significance of intestinal P-glycoprotein (P-gp) in determining the oral bioavailability of tacrolimus has been still controversial. in this study, we reevaluated the interaction of tacrolimus with P-gp in the rat small intestine, by evaluating its absorption from the rat small intestine and its modulating effect on the absorption of known P-gp substrates (digoxin, methylprednisolone, and vinblastine). Intestinal absorption of tacrolimus itself was as extensive as other P-gp modulators such as cyclosporine and verapamil. While cyclosporine and verapamil significantly increased the absorption of methylprednisolone and vinblastine through potent inhibition of intestinal P-gp, tacrolimus failed to achieve this. When cyclosporine and tacrolimus were intravenously administered to rats, digoxin absorption was significantly increased by cyclosporine but not by tacrolimus. When tacrolimus was coadministered with clotrimazole, a specific CYP3A inhibitor, into the rat small intestine, the area under the curve of tacrolimus blood concentrations increased more than sevenfold compared with that of tacrolimus alone. Our present results strongly suggest that the interaction between tacrolimus and P-gp is limited in the rat small intestine and that extensive metabolism by CYP3A enzymes is more responsible for the low oral bioavailability of tacrolimus. It was considered that the extensive absorption of cyclosporine and verapamil was closely associated with their potent ability to inhibit intestinal P-gp. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:34 / 42
页数:9
相关论文
共 46 条
  • [1] Arimoa H, 2001, J PHARMACOL EXP THER, V297, P547
  • [2] Asaumi J, 1996, ANTICANCER RES, V16, P247
  • [3] Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells
    Barnes, KM
    Dickstein, B
    Cutler, GB
    Fojo, T
    Bates, SE
    [J]. BIOCHEMISTRY, 1996, 35 (15) : 4820 - 4827
  • [4] Comparative tacrolimus pharmacokinetics: Normal versus mildly hepatically impaired subjects
    Bekersky, I
    Dressler, D
    Alak, A
    Boswell, G
    Mekki, QA
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (06) : 628 - 635
  • [5] Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
    Benet, LZ
    Cummins, CL
    Wu, CY
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) : 3 - 9
  • [6] Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
    Chiou, WL
    Chung, SM
    Wu, TC
    [J]. PHARMACEUTICAL RESEARCH, 2000, 17 (02) : 205 - 208
  • [7] Mechanisms of clinically relevant drug interactions associated with tacrolimus
    Christians, U
    Jacobsen, W
    Benet, LZ
    Lampen, A
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (11) : 813 - 851
  • [8] Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors
    Cormet-Boyaka, E
    Huneau, JF
    Mordrelle, A
    Boyaka, PN
    Carbon, C
    Rubinstein, E
    Tomé, T
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) : 2607 - 2611
  • [9] THE MDR1 GENE-PRODUCT, P-GLYCOPROTEIN, MEDIATES THE TRANSPORT OF THE CARDIAC GLYCOSIDE, DIGOXIN
    DELANNOY, IAM
    SILVERMAN, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 189 (01) : 551 - 557
  • [10] CYCLOSPORINE CLINICAL PHARMACOKINETICS
    FAHR, A
    [J]. CLINICAL PHARMACOKINETICS, 1993, 24 (06) : 472 - 495